Is Cencora, Inc. overvalued or undervalued?

As of 6 August 2025, the valuation grade for Cencora, Inc. has moved from very expensive to fair. Based on the current metrics, the company appears to be fairly valued. Key ratios include a P/E ratio of 44, an EV to EBITDA of 20.00, and a Price to Book Value of 78.87. In comparison, Boston Scientific Corp. has a significantly higher P/E of 73.71, while McKesson Corp. is rated risky with a P/E of 57.25.
Cencora's stock has outperformed the S&P 500 year-to-date with a return of 29.45% compared to the index's 12.22%, and over the past three years, it has achieved a remarkable 106.93% return versus the S&P 500's 70.41%. This performance reinforces the notion that the stock is fairly valued given its strong returns relative to the benchmark.